The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ustekinumab May Be Effective for Lupus

Ustekinumab May Be Effective for Lupus

November 12, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although treatments for systemic lupus erythematosus (SLE) exist, patients still have many unmet needs. The arsenal to treat SLE consists primarily of glucocorticoids and antimalarials, all of which are associated with considerable toxicity. Researchers have sought to improve SLE symptoms by targeting B cells with new drug treatments. One such drug is belimumab, a monoclonal antibody that targets B-lymphocyte activating factor and appears to be most effective in a subset of patients with greater serological and clinical disease activity at baseline.

You Might Also Like
  • Ustekinumab Found to Be Effective in Adolescents with Psoriasis
  • Tabalumab Modestly Effective in Systemic Lupus Erythematosus
  • Rontalizumab May Help Patients with Lupus & Low Interferon Signature
Also By This Author
  • Updated OARSI Guideline for the Non-Surgical Management of Osteoarthritis

Immunological abnormalities associated with SLE include an IFN-I signature, as well as involvement of both the interleukin (IL) 12 and IL-23 cytokine pathways. Ustekinumab, a monoclonal anti-IL-12 and anti-IL-23 antibody, is approved for use in adults with psoriatic arthritis and Crohn’s disease and adult and adolescent patients with plaque psoriasis. Results from a recent multicenter Phase 2 trial of 102 patients (ustekinumab, n=60; placebo, n=42) suggest the addition of ustekinumab to standard-of-care treatment for active SLE results in better efficacy than placebo. The study also revealed a safety profile consistent with the safety profile of ustekinumab therapy in other diseases. The results underscore the possibility that IL-12, IL-23 or both play important roles in the immunopathology of SLE. Ronald F. van Vollenhoven, professor of rheumatology at the Amsterdam University Medical Centers in the Netherlands, and colleagues published their findings online in Lancet.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators note the heterogeneous presentation of SLE can make it difficult to measure changes in disease activity and response to therapy. Therefore, they chose to look at global SLE disease activity responder index 2000 (SLEDAI-2K) and, specifically, the percentage of patients achieving a SLEDAI-2K responder index-4 (SRI-4) response. They also measured joint counts, mucocutaneous disease and disease flares, as well as C3 complement concentrations and anti-double stranded DNA autoantibodies at baseline and Week 24.

“To the best of our knowledge, this study is the first to report efficacy and safety of an anti-IL-12 and IL-23 antibody in SLE,” write the authors. “In this randomized controlled trial, a significantly greater proportion of ustekinumab-treated patients achieved the SRI-4 primary endpoint at Week 24 than those who received placebo, when added to standard-of-care therapy. Similarly, greater proportions of ustekinumab-treated patients achieved more stringent levels of global response (SRI-5 or SRI-6) at Week 24 than those who received placebo.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Specifically, at 24 weeks, 62% of patients in the ustekinumab group and 33% of patients in the placebo group achieved SRI-4 response. Unfortunately, the investigators found that the British Isles Lupus Assessment Group 2004 index-based combined lupus assessment (BICLA) response was not statistically different between the treatment and placebo groups.

Pages: 1 2 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Lupus, systemic lupus erythematosus (SLE), ustekinumab

You Might Also Like:
  • Ustekinumab Found to Be Effective in Adolescents with Psoriasis
  • Tabalumab Modestly Effective in Systemic Lupus Erythematosus
  • Rontalizumab May Help Patients with Lupus & Low Interferon Signature
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.